Login / Signup

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.

Ying ChengQiming WangKai LiJianhua ShiYing LiuLin WuBaohui HanGongyan ChenJianxing HeJie WangDonghua LouHao YuShanchun WangHaifeng QinXiaoling Li
Published in: British journal of cancer (2021)
ClinicalTrials.gov, number NCT03059797.
Keyphrases
  • placebo controlled
  • double blind
  • small cell lung cancer
  • clinical trial
  • phase iii
  • phase ii
  • study protocol
  • phase ii study
  • open label
  • randomized controlled trial
  • squamous cell carcinoma
  • rectal cancer